Physician profile
Libby Joffe
NPI 1831199645
$2,361.07
in general payments reported to CMS, 2019-2025
26 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $225 · 2021: $211 · 2022: $361 · 2023: $231 · 2024: $680 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.11 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $336.59 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $220.32 | 2020-2025 | |
| Optinose US, INC. | $213.79 | 2023-2024 | |
| Abbvie INC. | $163.27 | 2021-2023 | |
| Astellas Pharma US INC | $142.25 | 2020-2025 | Veozah |
| Glaxosmithkline, LLC. | $138.58 | 2020-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $136.15 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Allergan, INC. | $81.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.44 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $68.74 | 2023-2025 | Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $63.17 | 2019-2025 | Trintellix |
| Boston Scientific Corporation | $35.09 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Inspire Medical Systems, INC. | $30.31 | 2025 | Inspire |
| Amarin Pharma, INC. | $29.94 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.24 | 2020-2021 | |
| Exact Sciences Corporation | $23.20 | 2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $17.38 | 2025 | Xhance, Nuzyra |
| Phathom Pharmaceuticals, INC. | $16.30 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $14.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2022 | |
| Genentech USA, INC. | $13.84 | 2020 | |
| Amgen INC. | $13.78 | 2025 | Repatha |
| Vertical Pharmaceuticals, LLC | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Joffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.